ApoC-III and visceral adipose tissue contribute to paradoxically normal triglyceride levels in insulin-resistant African-American women

Nutrition & Metabolism

Frank M Sacks³  Marshall K Tulloch-Reid⁴  Novie Younger-Coleman⁴  Madia Ricks²  Amber B Courville¹  Jeremy D Furtado³  Anne E Sumner² 

[1] Nutrition Department, Clinical Center, National Institutes of Health, Bethesda, MD, USA;Diabetes, Endocrinology and Obesity Branch, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA;Harvard School of Public Health, Boston, MA, USA;Tropical Medicine Research Institute, University of the West Indies, Kingston, Jamaica

关键词: Health disparities;    African-Americans;    Insulin resistance;    Visceral adiposity;    Apoliprotein C-III;    Triglyceride;    Visceral adipose tissue;    ApoC-III;   

Others  :  802993
DOI  :  10.1186/1743-7075-10-73

 received in 2013-10-19, accepted in 2013-12-04,  发布年份 2013

【 摘 要 】

Background

African-Americans are more insulin-resistant than whites but have lower triglyceride (TG) concentrations. The metabolic basis for this is unknown. Our goal was to determine in a cross-sectional study the effect of insulin resistance, visceral adipose tissue (VAT) and the apolipoproteins, B, C-III and E, on race differences in TG content of very low density lipoproteins (VLDL).

Methods

The participants were 31 women (16 African-American, 15 white) of similar age (37 ± 9 vs. 38 ± 11y (mean ± SD), P = 0.72) and BMI (32.4 ± 7.2 vs. 29.3 ± 6.0 kg/m², P = 0.21). A standard diet (33% fat, 52% carbohydrate, 15% protein) was given for 7 days followed by a test meal (40% fat, 40% carbohydrate, 20% protein) on Day 8. Insulin sensitivity index (S_I) was calculated from the minimal model. VAT was measured at L2-3. The influence of race, S_I, VAT and apolipoproteins on the TG content of VLDL was determined by random effects models (REM).

Results

African-Americans were more insulin-resistant (S_I: 3.6 ± 1.3 vs. 5.6 ± 2.6 mU/L^-1.min^-1, P < 0.01) with less VAT (75 ± 59 vs. 102 ± 71 cm², P < 0.01). TG, apoB and apoC-III content of light and dense VLDL were lower in African-Americans (all P < 0.05 except for apoC-III in light VLDL, P = 0.11). ApoE content did not vary by race. In REM, VAT but not S_I influenced the TG concentration of VLDL. In models with race, S_I, VAT and all apolipoproteins entered, race was not significant but apoC-III and VAT remained significant determinants of TG concentration in light and dense VLDL.

Conclusions

Low concentrations of apoC-III and VAT in African-Americans contribute to race differences in TG concentrations.

Trial registration

ClinicalTrials.gov Identifier: NCT00484861

【 授权许可】

   
2013 Sumner et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Alberti KG, Eckel RH, Grundy SM, et al.: Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120:1640-1645.
• [2]Lemieux I, Pascot A, Couillard C, et al.: Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation 2000, 102:179-184.
• [3]Sumner AE, Cowie CC: Ethnic differences in the ability of triglyceride levels to identify insulin resistance. Atherosclerosis 2008, 196:696-703.
• [4]Osei K: Metabolic syndrome in blacks: are the criteria right? Curr Diab Rep 2010, 10:199-208.
• [5]Ukegbu UJ, Castillo DC, Knight MG, et al.: Metabolic syndrome does not detect metabolic risk in African men living in the U.S. Diabetes Care 2011, 34:2297-2299.
• [6]Yu SS, Ramsey NL, Castillo DC, Ricks M, Sumner AE: Triglyceride-based screening tests fail to recognize cardiometabolic disease in African immigrant and african-american men. Metab Syndr Relat Disord 2013, 11:15-20.
• [7]Sumner AE, Harman JL, Buxbaum SG, et al.: The triglyceride/high-density lipoprotein cholesterol ratio fails to predict insulin resistance in African-American women: an analysis of Jackson Heart Study. Metab Syndr Relat Disord 2010, 8:511-514.
• [8]Luc G, Fievet C, Arveiler D, et al.: Apolipoproteins C-III and E in apoB- and non-apoB-containing lipoproteins in two populations at contrasting risk for myocardial infarction: the ECTIM study. Etude Cas Temoins sur ‘Infarctus du Myocarde. J Lipid Res 1996, 37:508-517.
• [9]Sacks FM, Alaupovic P, Moye LA, et al.: VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation 2000, 102:1886-1892.
• [10]Adiels M, Olofsson SO, Taskinen MR, Boren J: Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008, 28:1225-1236.
• [11]Despres JP, Lemieux I: Abdominal obesity and metabolic syndrome. Nature 2006, 444:881-887.
• [12]Chow CC, Periwal V, Csako G, et al.: Higher acute insulin response to glucose may determine greater free Fatty Acid clearance in African-American women. J Clin Endocrinol Metab 2011, 96:2456-2463.
• [13]Zheng C, Ikewaki K, Walsh BW, Sacks FM: Metabolism of apoB lipoproteins of intestinal and hepatic origin during constant feeding of small amounts of fat. J Lipid Res 2006, 47:1771-1779.
• [14]Alaupovic P: Significance of apolipoproteins for structure, function, and classification of plasma lipoproteins. Methods Enzymol 1996, 263:32-60.
• [15]Campos H, Perlov D, Khoo C, Sacks FM: Distinct patterns of lipoproteins with apoB defined by presence of apoE or apoC-III in hypercholesterolemia and hypertriglyceridemia. J Lipid Res 2001, 42:1239-1249.
• [16]Zheng C, Khoo C, Ikewaki K, Sacks FM: Rapid turnover of apolipoprotein C-III-containing triglyceride-rich lipoproteins contributing to the formation of LDL subfractions. J Lipid Res 2007, 48:1190-1203.
• [17]Clavey V, Lestavel-Delattre S, Copin C, Bard JM, Fruchart JC: Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII, and E. Arterioscler Thromb Vasc Biol 1995, 15:963-971.
• [18]Zheng C, Khoo C, Furtado J, Sacks FM: Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype. Circulation 2010, 121:1722-1734.
• [19]Altomonte J, Cong L, Harbaran S, et al.: Foxo1 mediates insulin action on apoC-III and triglyceride metabolism. J Clin Invest 2004, 114:1493-1503.
• [20]Dallinga-Thie GM, Groenendijk M, Blom RN, De Bruin TW, De Kant E: Genetic heterogeneity in the apolipoprotein C-III promoter and effects of insulin. J Lipid Res 2001, 42:1450-1456.
• [21]Li WW, Dammerman MM, Smith JD, Metzger S, Breslow JL, Leff T: Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. J Clin Invest 1995, 96:2601-2605.
• [22]Sumner AE, Luercio MF, Frempong BA, et al.: Validity of the reduced-sample insulin modified frequently-sampled intravenous glucose tolerance test using the nonlinear regression approach. Metabolism 2009, 58:220-225.
• [23]Boston RC, Stefanovski D, Moate PJ, Sumner AE, Watanabe RM, Bergman RN: MINMOD Millennium: a computer program to calculate glucose effectiveness and insulin sensitivity from the frequently sampled intravenous glucose tolerance test. Diabetes Technol Ther 2003, 5:1003-1015.
• [24]Dietary Reference Intakes: The Essential Guide to Nutrient Requirements. The National Academies Press; 2006. http://www.nap.edu/openbook.php?record_id=11537 webcite
• [25]Mifflin MD, St Jeor ST, Hill LA, Scott BJ, Daugherty SA, Koh YO: A new predictive equation for resting energy expenditure in healthy individuals. Am J Clin Nutr 1990, 51:241-247.
• [26]Cordain L, Eaton SB, Sebastian A, et al.: Origins and evolution of the Western diet: health implications for the 21st century. Am J Clin Nutr 2005, 81:341-354.
• [27]Nielsen S, Sumner AE, Miller BV III, Turkova H, Klein S, Jensen MD: Free fatty acid flux in African American and Caucasian adults - effect of sex and race. Obesity (Silver Spring) 2013, 21:1836-1842.
• [28]Sumner AE, Sen S, Ricks M, Frempong BA, Sebring NG, Kushner H: Determining the waist circumference in African Americans which best predicts insulin resistance. Obesity (Silver Spring) 2008, 16:841-846.
• [29]Guerrero R, Vega GL, Grundy SM, Browning JD: Ethnic differences in hepatic steatosis: an insulin resistance paradox? Hepatology 2009, 49:791-801.
• [30]Lee SJ, Campos H, Moye LA, Sacks FM: LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients. Arterioscler Thromb Vasc Biol 2003, 23:853-858.
• [31]Mendivil CO, Rimm EB, Furtado J, Chiuve SE, Sacks FM: Low-density lipoproteins containing apolipoprotein C-III and the risk of coronary heart disease. Circulation 2011, 124:2065-2072.
• [32]Mahley RW, Rall SC Jr: Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet 2000, 1:507-537.
• [33]Furtado JD, Campos H, Sumner AE, Appel LJ, Carey VJ, Sacks FM: Dietary interventions that lower lipoproteins containing apolipoprotein C-III are more effective in whites than in blacks: results of the OmniHeart trial. Am J Clin Nutr 2010, 92:714-722.